Should You Buy Eli Lilly Before Aug. 8?

05:10am, Monday, 05'th Aug 2024
Eli Lilly shares have soared more than 230% over the past three years. The company has generated major growth thanks to its weight loss drugs.
NEW YORK, NY / ACCESSWIRE / August 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lill
My initial bearish thesis about Eli Lilly stock did not age well, as the stock has performed well since February despite being substantially overvalued. However, the market appears to be comfortable w
A clinical trial starring patients with both obesity and heart failure says treatment with tirzepatide provides a big risk reduction. Tirzepatide is the active ingredient in both Mounjaro, a diabetes
With a rich history dating back to the 19th century, Eli Lilly (LLY) has faced struggles and successes. But a booming market cap has quickly turned it into the biggest pharmaceutical brand in the worl
A recent study compared the effectiveness of tirzepatide against semaglutide. Tirzepatide has been more effective in helping people lose weight in trials, and the study corroborated that.
Eli Lilly is a giant in the world of weight loss drugs, generating billions of dollars in revenue. Rival big pharma player Pfizer aims to get in on this major market.
All doses of Eli Lilly's highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the Food and Drug Administration's drug short
NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQ: MORF) and Eli
All doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortage list showed on Friday.
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lill
The pharmaceutical giant's CEO had some very good news to report about a hot product. The medication should come off the FDA's shortage list in the immediate future, according to him.
Jared Holz, Mizuho, joins 'Fast Money' to talk resilience in the health care sector as the broader market sees a sell-off.
Easily one of the biggest trends right now in the field of medicine is the weight loss drug surge. Without attempting to sound cynical, the reality is that the sector enjoys a massive total addressabl
U.S. drugmaker Eli Lilly expects its blockbuster weight-loss drug to officially come out of shortage in the United States in coming days, Bloomberg News reported on Thursday, citing an interview with
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE